Skip to main content
Article
Validation of an Endometrial Tumor Diameter Model for Risk Assessment in the Absence of Lymph Node Mapping
Journal of Patient-Centered Research and Reviews
  • McKayla J Riggs, Brooke Army Medical Center
  • Callie M Cox Bauer, Brooke Army Medical Center; Aurora Sinai Medical Center
  • Caela R Miller, Brooke Army Medical Center
  • James K Aden, Brooke Army Medcial Center
  • Scott A Kamelle, Aurora St. Luke's Medical Center
Publication Date
10-23-2020
Keywords
  • endometrioid endometrial cancer,
  • lymph node involvement,
  • tumor diameter,
  • lymphadenectomy
Abstract

Purpose: This study aimed to assess the optimal tumor diameter for predicting lymphatic metastasis and to determine intraoperatively the need for lymph node dissection in patients with endometrioid endometrial cancer.

Methods: Military beneficiaries diagnosed with stage I–III endometrioid endometrial cancer during 2003–2016 who had at least 7 pelvic and/or paraaortic lymph nodes removed during the time of hysterectomy were studied. Tumor diameter was compared against the presence of positive nodes, using the prior models of 20 mm (ie, Mayo model) and 50 mm (ie, Milwaukee model), to determine the false-negative rate of each threshold. A separate analysis was completed to determine the optimal diameter for our population. Receiver operating characteristic curve analysis models of tumor diameter were evaluated for model fit and predictive power of lymph node involvement.

Results: Of the 1224 patients with endometrioid endometrial cancer included, 13% (n = 160) had positive lymph node involvement. Tumor sizes ranged from 1 mm to 100 mm. In contrast to Mayo and Milwaukee models (ie, Mayo, Milwaukee), the optimal tumor diameter independent of myometrial invasion and grade of tumor to predict lymph node metastasis was found to be 35 mm.

Conclusions: Endometrioid endometrial cancer tumor diameter of 35 mm was found to be the optimal threshold for lymphadenectomy when the operating surgeon has no knowledge of tumor invasion.

Citation Information

Riggs MJ, Cox Bauer CM, Miller CR, Aden JK, Kamelle SA. Validation of an endometrial tumor diameter model for risk assessment in the absence of lymph node mapping. J Patient Cent Res Rev. 2020;7:323-8. doi: 10.17294/2330-0698.1768